Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | PGR | P06401 | 3/20 | 0.60 |
| ▸ | BRD4 | O60885 | 1/20 | 0.59 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | GFER | P55789 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | PAK4 | O96013 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | LTK | P29376 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1859217 | 0.83 | PGR (0.68) | MAPTPGRBRD4HSD17B2ALDH1A1 | |
| SCHEMBL8279529 | 0.82 | MAPT (0.70) | TDP1MAPTLMNAPGRALDH1A1 | |
| SCHEMBL2832955 | 0.81 | MAPT (0.73) | TDP1MAPTLMNAALDH1A1GFER | |
| SCHEMBL5718766 | 0.81 | ALDH1A1 (0.73) | TDP1MAPTLMNAPGRALDH1A1 | |
| SCHEMBL1403074 | 0.81 | PGR (0.75) | MAPTPGRBRD4HSD17B2ALDH1A1 | |
| SCHEMBL30565215 | 0.81 | PGR (0.75) | MAPTPGRBRD4HSD17B2ALDH1A1 | |
| SCHEMBL94971 | 0.80 | PGR (0.65) | PGRBRD4HSD17B2ALDH1A1PKM | |
| SCHEMBL22441735 | 0.80 | PGR (0.72) | TDP1MAPTLMNAPGRBRD4 | |
| SCHEMBL1489068 | 0.80 | PGR (0.65) | MAPTPGRBRD4HSD17B2ALDH1A1 | |
| SCHEMBL28121844 | 0.80 | PKM (0.72) | MAPTPGRBRD4HSD17B2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023735-A1 | Sulphonamide Derivatives | BIOTIE THERAPIES CORP. (FI) | 2009-01-22 | — | — | US | disclosed |
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| EP-1924554-A1 | SULPHONAMIDE DERIVATIVES | Biotie Therapies Corp. (FI) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007034035-A1 | SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2007-03-29 | — | — | WO | disclosed |
| EP-1732884-A1 | SULPHONAMIDE DERIVATIVES | Biotie Therapies Corp. (FI) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005090298-A1 | SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005090297-A1 | SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | NR1I2, ITGA2, ITGB2 | TDP1 4009/4885MAPT 4739/4885LMNA 3369/4885 |
| US-20090023735-A1 | Sulphonamide Derivatives | HCAR1, ADGRE5, ALK | TDP1 4726/4885MAPT 4881/4885LMNA 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.